Biogen (BIIB) PT Raised to $300 at Jefferies Post Q3

October 29, 2013 12:16 PM

Jefferies lifted its price target on Buy-rated Biogen (NASDAQ: BIIB) from $270 to $300 following solid Q3 results.

"BIIB ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found